公告显示，交易对手方是恩沐生物（Chimagen Biosciences），标的是①The total value of this trade can reach up to 0.85 billion US dollars, with an initial payment of 0.3 billion US dollars; ②This acquisition will further expand GSK's own pipeline for the treatment of autoimmune diseases; ③With the global recognition of China's biomedical research and development capabilities, such trades have been rapidly growing in recent years.
Finance Association news on October 29th (Editor Shi Zhengcheng) multinational pharmaceutical giant GlaxoSmithKline (GSK) announced on Tuesday that it has reached an agreement with a Chinese biomedical company to acquire an innovative drug for systemic lupus erythematosus, with a potential transaction value of up to 0.85 billion US dollars.
(Source: GSK official website)
The announcement shows that the counterparty of the trade is Chimagen Biosciences, and the target is the dual-target CD19/CD20 T-cell mediated antibody CMG1A46.
The initial payment for the trade is 0.3 billion US dollars, and subsequently Chimagen Biosciences will be eligible to receive funds related to drug development and commercial milestones, totaling 0.55 billion US dollars.
This acquisition will expand GSK's own pipeline for the treatment of autoimmune diseases. Currently, the company already has a best-selling systemic lupus erythematosus drug Tremfya (Guselkumab). GSK plans to further develop and commercialize CMG1A46, focusing on B cell-driven autoimmune diseases such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), as well as expanding into the potential of related autoimmune diseases.
The company stated that there are still unmet needs for lupus patients, especially for those who do not respond to current standard treatments.
It is reported that CMG1A46 is undergoing Phase I clinical trials for leukemia and lymphoma in China. GSK plans to conduct Phase I clinical trials for systemic lupus erythematosus in the first quarter of 2025.
Biomedical giants are turning their attention to China.
With the increasing R&D strength of China's biomedical industry, more and more large multinational pharmaceutical companies are frequently setting their sights on China.
In December last year, Shanghai Hansoh Biomedical announced a licensing agreement with GSK, involving the overseas licensing of ADC (antibody-drug conjugate) drug HS-20093, with a transaction amount of up to $1.7 billion. And at the end of October last year, Hansoh Biomedical reached an exclusive licensing agreement with GSK for another ADC new drug HS-20089, with a maximum agreement value exceeding $1.5 billion.
According to media statistics at the time, as an emerging track for cancer treatment, the total value of domestic pharmaceutical companies' ADC drugs in "going global transactions" has exceeded $35 billion.
In the US stock market, there was once a capital myth related to Chinese pharmaceuticals going global this year. A stock named Summit Pharmaceuticals (SMMT) saw its stock price rise from $3 to over $30 at one point during the year, with the latest quote at $21.
(SMMT daily chart, Source: TradingView)
According to a mid-September report by Caixin, the latest surge in the company was due to the World Conference on Lung Cancer (WCLC) in September. Clinical studies presented at the conference showed that Summit Pharmaceuticals, in collaboration with Akeso, developed the world's first PD-1/VEGF bispecific antibody drug, ivosidenib, which won the treatment comparison for non-small cell lung cancer against Merck's pembrolizumab, also known in the industry as "K drug".
Pembrolizumab was last year's "global drug king," with sales of $25 billion surpassing simiglucose.
In this collaboration, it is still Chinese pharmaceutical companies that showcase the power of "medical innovation". Akeso licensed a portion of the overseas rights to Ivosidenib to Summit Pharmaceuticals at the end of 2022, obtaining a sales commission agreement of over 5 billion US dollars, setting a record for Chinese pharmaceutical companies' overseas cooperation at the time.
By the way, the successful cooperation with Chinese pharmaceutical companies has also skyrocketed the net worth of Bob Duggan, co-founder of Summit Pharmaceuticals, to 15 billion US dollars, ranking 138th on the global rich list.
According to the latest news at the end of October, Duggan spent 33 million US dollars to purchase one of the most expensive penthouses in the Miami area, with an interior area of 1022 square meters. This top-floor apartment on the 57th floor features five bedrooms and an indoor swimming pool.
(Source: zillow)
